Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PDL BioPharma nets $291mm through notes offering

Executive Summary

PDL BioPharma Inc. (manages antibody humanization patents; realizes revenue through royalties) netted $291mm through the public sale of $300mm aggregate amount (including the overallotment) of its 4% senior notes due February 1, 2018. Each $1k of notes converts into 109.1048 common shares, equal to a conversion rate of $9.17 per share. (PDL's stock averaged $8.95 at the time of the sale.)
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO
    • Convertible Debt

Related Companies